Skip to main content

Table 4 Types and number of drugs received during the hospitalisation

From: A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial

 

Cholecalciferol group

Control group

n

n=274

n

n=269

Drugs prescribed

 Cholecalciferol, n (%)

274

274 (100.0)

269

0 (0.0)

 Enoxaparin, n (%)

270

210 (77.8)

264

191 (72.3)

 Ceftriaxone, n (%)

271

100 (36.9)

264

94 (35.6)

 Methylprednisolone, n (%)

271

99 (36.5)

265

94 (35.5)

 Azithromycin, n (%)

272

88 (32.4)

265

97 (36.6)

 Dexamethasone, n (%)

272

83 (30.5)

265

78 (29.4)

 Number of drugs per patient, median [IQR]

272

2.0 [2.0, 3.0]

265

2.0 [2.0, 3.0]

  1. The therapies used in less than 10% of patients (hydroxychloroquine N=48, lopinavir, ritonavir N=36, tocilizumab N=25 or plasma from convalescent patients N=53) were not included in the table
  2. n number of patients available for analysis, IQR interquartile range